The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•6 April 2026•

1 min read

Moderna Faces Revenue Decline Amid Strategic Pivot to mRNA Pipeline

Key Facts

1Spikevax 2024 sales reached $3.1B.

2RSV vaccine sales were a major disappointment at $25M.

32025 revenue dropped 40% YoY to $1.9B.

4The company maintains robust liquidity with $8.1B in cash and investments.

Moderna is navigating a challenging financial landscape as demand for its COVID-19 vaccine continues to normalize, with Spikevax sales reaching $3.1 billion in 2024. Projections for 2025 indicate a significant 40% year-over-year revenue drop to $1.9 billion, highlighting the difficulty of the post-pandemic transition. Furthermore, the launch of its RSV vaccine underperformed expectations, generating only $25 million in sales. Despite these headwinds, the company maintains a robust liquidity position with $8.1 billion in cash and investments. This substantial capital reserve provides a critical safety net to fund future mRNA development projects and clinical trials. Investors remain focused on whether Moderna's broader pipeline can effectively offset the diminishing returns from its pandemic-era portfolio.

Create Free Account